Integrating liquid biopsies into the management of cancer

By G. Siravegna, S. Marsoni, S. Siena, A. Bardelli. Nature Reviews Clinical Oncology, 2017

1,742 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Innovative approaches for cancer treatment: current perspectives and new challenges (2019, methodology): “Liquid biopsies to detect circulating tumour cells, RNAs, DNAs and exosomes have been used as indicators for personalised medicine [63].”
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments (2022, background): “Limitations associated with isolation and analysis of extremely low levels of ctDNA have to a large extent been reduced by ever-evolving technological applications [4, 96].”
Enhanced detection of circulating tumor DNA by fragment size analysis (2018, background): “INTRODUCTION Blood plasma of patients with cancer contains circulating tumor DNA (ctDNA), but this valuable source of information is diluted by much larger quantities of DNA of noncancerous origins, such that ctDNA usually represents only a small fraction of the total cell-free DNA (cfDNA) (1, 2).”
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. (2018, background): “95%.(21) Cross-platform comparisons have been undertaken in a few small studies, with high concordance between assays for specific variants with discrepancies largely explained by differences in analytical sensitivity among assays.”